search
Back to results

Stem Cell Therapy to Improve Burn Wound Healing

Primary Purpose

Skin Burn Degree Second

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Allogeneic (MSC's) Application to the Burn Wounds
Sponsored by
E.Badiavas
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Skin Burn Degree Second focused on measuring Skin Burn Degree Second, Second degree Burn, Burn wound

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

- Donors:

Eligibility Criteria:

  • No history of malignancy
  • No active coagulopathy and/or hypocoagulable state
  • No history of cardio/pulmonary conditions
  • Negative tests for Hepatitis A, Hepatitis B, Hepatitis C, RPR, HIV 1 / 2, HTLV I/II, Chagas Disease, NAT for HCV, HIV and WNV.
  • Hemoglobin ≥ 13.0 g/dL
  • Platelet count 140,000 to 440,000/ul
  • WBC 3.0 to 11.0 K/ul
  • BNP ≤ 100 pg /mL
  • No anomalies on the CBC and differential suggestive of a hematopoietic disorder
  • Creatinine ≤ 1.5 mg/dL
  • ALT ≤ 112 IU/L
  • AST ≤ 100 IU/L
  • Bilirubin < 1.5 mg/dL
  • No diabetes
  • Systolic blood pressure ≤ 170
  • Diastolic blood pressure ≤ 90
  • No history of autoimmune disorders

Recipients:

Inclusion Criteria:

  1. Male or female subjects 18 years of age or older with Superficial, Intermediate or Deep 2nd Degree Burn Wounds
  2. Injury within the prior 7 days
  3. Subjects must understand and give written informed consent.
  4. Subjects must agree to have biopsies performed as per protocol
  5. Subjects must be accessible for weekly wound treatment and assessment visits
  6. Males and females must agree to use an acceptable method of contraception. Exceptions will be females of non-childbearing age and monogamous males who are partners of females of non-childbearing age. Acceptable methods of birth control include; history of sterilization, birth control pills, depoprogesterone injections, a barrier contraceptive such as a condom with or without spermicide cream or gel, diaphragms or cervical cap with or without spermicide cream or gel, or an intrauterine device (IUD).
  7. Maximum wound size limited to:

    • Single wound: ≤ 5% body surface area (BSA)
    • Multiple wounds treated in a defined anatomical region with ≤ 20% cumulative BSA.
  8. Diabetic subjects: HbA1c ≤ 8%

Exclusion Criteria:

  1. Solely 1st degree or solely 3rd degree burns
  2. Subjects with superficial 2nd degree burn who are expected to heal within 2 weeks post standard therapy
  3. Evidence of active infection at the wound site
  4. Evidence of significant wound healing prior to treatment
  5. Wound located in the area of fingers, toes, face, or perineum
  6. Wound where 75% or more extends across joints
  7. Electrical or chemical burns
  8. Have any requirement for the use of systemic steroids or immunosuppressive
  9. Subjects Allergic to human albumin, streptomycin, or penicillin
  10. Be a pregnant female or nursing mother
  11. Subjects who are known or found to be HIV positive
  12. Current history of alcohol or substance abuse or history of alcohol or substance abuse requiring treatment within the past 12 months
  13. Patients with severe medical conditions

    1. Malignancy (other than non melanoma skin cancer) not in remission or in remission less than 5 years
    2. Life expectancy less than two years
    3. Severe cardiopulmonary disease restricting ambulation to the clinical facility
  14. WBC <3 or > 10 x10⁹/L, Hgb < 9g/dL, platelets count 100x10⁹/L or less, serum creatinine > 1.5 times the upper normal limit, AST or ALT > 2.5 times the upper normal limit.
  15. Subjects with abnormal bilirubin levels.
  16. Subjects with abnormal PT/INR laboratory values while not on chronic anticoagulant treatment which can be held for minor surgical procedures
  17. Those with a known history of coagulopathy
  18. Subjects who are potential recipients of tissue or organ transplantation
  19. Subjects with circulating Hepatitis B antigen and/or who are seropositive for Hepatitis C antibody
  20. History of poor compliance, unreliability

Sites / Locations

  • University of Miami

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Allogeneic (MSC's) Application to the Burn Wounds

Arm Description

Allogeneic (MSC's) Application to the Burn Wounds. The 1st group of 5 will be started on the lowest dose. If there are no adverse reactions, the 2nd group of 5 will receive a higher dose. This will be repeated for the 3rd and 4th groups with each receiving a higher dose. Up to 2 administrations of cells per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart.

Outcomes

Primary Outcome Measures

Monitoring for adverse events as Assessed by CTCAE v4.0 following administration of allogeneic MSCs to 2nd degree burn wounds.
The study will consist of a dose escalation phase consisting of four dose levels. Each dose level will compare the safety of administering allogeneic MSCs, with 5 patients per group.

Secondary Outcome Measures

Full Information

First Posted
April 1, 2014
Last Updated
April 28, 2020
Sponsor
E.Badiavas
Collaborators
United States Department of Defense
search

1. Study Identification

Unique Protocol Identification Number
NCT02104713
Brief Title
Stem Cell Therapy to Improve Burn Wound Healing
Official Title
A Pilot Safety Study of the Administration of Mesenchymal Stem Cells (MSC) in the Treatment of Burn Wounds
Study Type
Interventional

2. Study Status

Record Verification Date
April 2020
Overall Recruitment Status
Completed
Study Start Date
June 4, 2014 (Actual)
Primary Completion Date
March 18, 2019 (Actual)
Study Completion Date
March 18, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
E.Badiavas
Collaborators
United States Department of Defense

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will determine the safety of allogeneic stem cell therapy from healthy donors, for 2nd degree burn wounds of less than 20% Total Body Surface Area (TBSA), at four different dose levels. Clinical evaluation will take place every 1 to 4 weeks intervals until wound closure, and then monthly for 6 months following the last administration of MSCs. Once the safety and dose-response analysis in Phase 1 is completed, an expanded trial will be initiated to better examine the efficacy of MSC therapy in 2nd degree burn wounds. Phase 1 will establish the maximum safe dose that will be used in the Phase II trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Skin Burn Degree Second
Keywords
Skin Burn Degree Second, Second degree Burn, Burn wound

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Allogeneic (MSC's) Application to the Burn Wounds
Arm Type
Experimental
Arm Description
Allogeneic (MSC's) Application to the Burn Wounds. The 1st group of 5 will be started on the lowest dose. If there are no adverse reactions, the 2nd group of 5 will receive a higher dose. This will be repeated for the 3rd and 4th groups with each receiving a higher dose. Up to 2 administrations of cells per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart.
Intervention Type
Biological
Intervention Name(s)
Allogeneic (MSC's) Application to the Burn Wounds
Other Intervention Name(s)
Stem Cells Application to the Burn Wounds
Intervention Description
Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm. Second dose level 5 X 10³ Allogeneic MSCs cells/square cm. Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm. Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm. Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart.
Primary Outcome Measure Information:
Title
Monitoring for adverse events as Assessed by CTCAE v4.0 following administration of allogeneic MSCs to 2nd degree burn wounds.
Description
The study will consist of a dose escalation phase consisting of four dose levels. Each dose level will compare the safety of administering allogeneic MSCs, with 5 patients per group.
Time Frame
1.5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
- Donors: Eligibility Criteria: No history of malignancy No active coagulopathy and/or hypocoagulable state No history of cardio/pulmonary conditions Negative tests for Hepatitis A, Hepatitis B, Hepatitis C, RPR, HIV 1 / 2, HTLV I/II, Chagas Disease, NAT for HCV, HIV and WNV. Hemoglobin ≥ 13.0 g/dL Platelet count 140,000 to 440,000/ul WBC 3.0 to 11.0 K/ul BNP ≤ 100 pg /mL No anomalies on the CBC and differential suggestive of a hematopoietic disorder Creatinine ≤ 1.5 mg/dL ALT ≤ 112 IU/L AST ≤ 100 IU/L Bilirubin < 1.5 mg/dL No diabetes Systolic blood pressure ≤ 170 Diastolic blood pressure ≤ 90 No history of autoimmune disorders Recipients: Inclusion Criteria: Male or female subjects 18 years of age or older with Superficial, Intermediate or Deep 2nd Degree Burn Wounds Injury within the prior 7 days Subjects must understand and give written informed consent. Subjects must agree to have biopsies performed as per protocol Subjects must be accessible for weekly wound treatment and assessment visits Males and females must agree to use an acceptable method of contraception. Exceptions will be females of non-childbearing age and monogamous males who are partners of females of non-childbearing age. Acceptable methods of birth control include; history of sterilization, birth control pills, depoprogesterone injections, a barrier contraceptive such as a condom with or without spermicide cream or gel, diaphragms or cervical cap with or without spermicide cream or gel, or an intrauterine device (IUD). Maximum wound size limited to: Single wound: ≤ 5% body surface area (BSA) Multiple wounds treated in a defined anatomical region with ≤ 20% cumulative BSA. Diabetic subjects: HbA1c ≤ 8% Exclusion Criteria: Solely 1st degree or solely 3rd degree burns Subjects with superficial 2nd degree burn who are expected to heal within 2 weeks post standard therapy Evidence of active infection at the wound site Evidence of significant wound healing prior to treatment Wound located in the area of fingers, toes, face, or perineum Wound where 75% or more extends across joints Electrical or chemical burns Have any requirement for the use of systemic steroids or immunosuppressive Subjects Allergic to human albumin, streptomycin, or penicillin Be a pregnant female or nursing mother Subjects who are known or found to be HIV positive Current history of alcohol or substance abuse or history of alcohol or substance abuse requiring treatment within the past 12 months Patients with severe medical conditions Malignancy (other than non melanoma skin cancer) not in remission or in remission less than 5 years Life expectancy less than two years Severe cardiopulmonary disease restricting ambulation to the clinical facility WBC <3 or > 10 x10⁹/L, Hgb < 9g/dL, platelets count 100x10⁹/L or less, serum creatinine > 1.5 times the upper normal limit, AST or ALT > 2.5 times the upper normal limit. Subjects with abnormal bilirubin levels. Subjects with abnormal PT/INR laboratory values while not on chronic anticoagulant treatment which can be held for minor surgical procedures Those with a known history of coagulopathy Subjects who are potential recipients of tissue or organ transplantation Subjects with circulating Hepatitis B antigen and/or who are seropositive for Hepatitis C antibody History of poor compliance, unreliability
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carl Schulman, MD, PhD
Organizational Affiliation
University of Miami
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Miami
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28602587
Citation
Maranda EL, Wang MX, Shareef S, Tompkins BA, Emerson C, Badiavas EV. Surgical management of leukoderma after burn: A review. Burns. 2018 Mar;44(2):256-262. doi: 10.1016/j.burns.2017.05.004. Epub 2017 Jun 8.
Results Reference
derived

Learn more about this trial

Stem Cell Therapy to Improve Burn Wound Healing

We'll reach out to this number within 24 hrs